Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct;21(5):e691-703.
doi: 10.3747/co.21.1997.

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer

M A Socinski
Review

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer

M A Socinski. Curr Oncol. 2014 Oct.

Abstract

Based on demonstrated favourable risk-benefit profiles, taxanes remain a key component in the first-line standard of care for advanced non-small-cell lung cancer (nsclc) and nsclc subtypes. In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or meta-static nsclc. The approval was granted because of demonstrated improved antitumour activity and tolerability compared with solvent-based paclitaxel-carboplatin in a phase iii trial. This review focuses on the evolution of first-line taxane therapy for advanced nsclc and the new options and advances in taxane therapy that might address unmet needs in advanced nsclc.

Keywords: Docetaxel; elderly patients; nab-paclitaxel; paclitaxel; squamous cell carcinoma.

PubMed Disclaimer

References

    1. Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) Bethesda, MD: National Cancer Institute; 2012.
    1. American Cancer Society . Learn About Cancer > Lung Cancer–Non-Small Cell > Detailed Guide > What is non-small cell lung cancer? [Web resource] Atlanta, GA: American Cancer Society; 2012. [Current version available at: http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/non-...; cited May 15, 2012]
    1. Quoix E. Optimal pharmacotherapeutic strategies for elderly patients with advanced non-small cell lung cancer. Drugs Aging. 2011;28:885–94. doi: 10.2165/11595100-000000000-00000. - DOI - PubMed
    1. Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008;3:125–9. doi: 10.1097/JTO.0b013e3181622c17. - DOI - PubMed
    1. Azzoli CG, Baker S, Jr, Temin S, et al. on behalf of the American Society of Clinical Oncology American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage iv non-small-cell lung cancer. J Clin Oncol. 2009;27:6251–66. doi: 10.1200/JCO.2009.23.5622. - DOI - PMC - PubMed